一种新型离体试验利用表达Pvs25的转基因伯氏疟原虫评估间日疟原虫传播阻断疫苗的功能有效性
研究开发了表达Pvs25的转基因伯氏疟原虫(TgPbvs25),并优化参数建立离体膜饲喂试验(MFA),用于评估基于Pvs25抗原的间日疟原虫传播阻断疫苗(TBV),有望摆脱对疫区间日疟患者血液的依赖。
要点
- 转基因伯氏疟原虫表达Pvs25可作为评估间日疟原虫TBV的替代平台
- 优化参数后建立离体膜饲喂试验用于评估Pvs25-based TBV
- 该试验有望加速Pvs25 TBV开发且不依赖疫区患者血液
核心结论
- 离体膜饲喂试验有望在不依赖疫区间日疟原虫感染者血液的情况下加速基于Pvs25的传播阻断疫苗开发。
研究设计与样本
- 开发表达Pvs25的转基因伯氏疟原虫(TgPbvs25)并优化参数建立离体膜饲喂试验。
主要发现
- 成功开发具有传播能力的转基因TgPbvs25寄生虫。
- 优化参数后建立了基于Pvs25抗原评估间日疟原虫TBV的离体膜饲喂试验。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plasmodium falciparum and Plasmodium vivax account for >90% global malaria burden. Transmission intervention strategies encompassing transmission-blocking vaccines (TBV) and drugs represent ideal public health tools to eliminate malaria at the population level. The availability of mature P. falciparum gametocytes through in vitro culture has facilitated development of a standard membrane feeding assay to assess efficacy of transmission interventions against P. falciparum. The lack of in vitro culture for P. vivax has significantly hampered similar progress on P. vivax and limited studies have been possible using blood from infected patients in endemic areas. The ethical and logistical limitations of on-time access to blood from patients have impeded the development of P. vivax TBVs. METHODS: Transgenic murine malaria parasites (Plasmodium berghei) expressing TBV candidates offer a promising alternative for evaluation of P. vivax TBVs through in vivo studies in mice, and ex vivo membrane feeding assay (MFA). RESULTS: We describe the development of transmission-competent transgenic TgPbvs25 parasites and optimization of parameters to establish an ex vivo MFA to evaluate P. vivax TBV based on Pvs25 antigen. CONCLUSIONS: The MFA is expected to expedite Pvs25-based TBV development without dependence on blood from P. vivax-infected patients in endemic areas for evaluation.
引用
- Cao Y, Hayashi CTH, Kumar N, et al. A Novel Ex Vivo Assay to Evaluate Functional Effectiveness of Plasmodium vivax Transmission-Blocking Vaccine Using Pvs25 Transgenic Plasmodium berghei. J Infect Dis. 2024. PMID: 38408353. doi:10.1093/infdis/jiae102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。